Lucid Diagnostics Inc. (LUCD) vs Outlook Therapeutics, Inc. (OTLK)
A side-by-side comparison of Lucid Diagnostics Inc. and Outlook Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
LUCD
Lucid Diagnostics Inc.
$0.60HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
OTLK
Outlook Therapeutics, Inc.
$0.57HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — LUCD vs OTLK
growth of $100 · dividends reinvested · last 5yLUCD -95.0% (-45.0%/yr)OTLK -98.6% (-57.5%/yr)LUCD compounded faster over this window
LUCD OTLK
LUCD vs OTLK: by the numbers
- •LUCD is the larger company ($114M vs $107M market cap).
- •Both run net losses; LUCD's is the smaller (-959.76% vs -4416.22% net margin).
Metrics side by side
Valuation
| Metric | LUCD | OTLK |
|---|---|---|
| P/S ratio | 21.02 | N/A |
| P/B ratio | 10.48 | N/A |
Profitability
| Metric | LUCD | OTLK |
|---|---|---|
| Gross margin | -60.26% | 46.49% |
| Operating margin | -1054.82% | -4744.25% |
| Net margin | -959.76% | -4416.22% |
| ROE | -478.26% | N/A |
| ROIC | -145.10% | -352.19% |
Growth (annualized)
| Metric | LUCD | OTLK |
|---|---|---|
| Total return CAGR (5Y) | N/A | -57.40% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.